Alison Moore - Allogene Therapeutics Chief Technical Officer
| ALLO Stock | USD 1.87 0.03 1.63% |
Executive
Dr. Alison Moore, Ph.D., serves as Chief Technical Officer of the Company, She has served as our Chief Technical Officer since June 2018. Prior to joining us, she most recently served as Senior Vice President, Process Development at Amgen Inc. from January 2013 until June 2018. Dr. Moore has previously held senior roles at Amgen in Operations Technology from January 2013 until August 2014, Process and Product engineering from January 2011 until January 2013, and Corporationrationrate Manufacturing from August 2008 until December 2010. Prior to these positions, she was Vice President, Site Operations at Amgens Fremont, California, manufacturing facility, from March 2006 until August of 2008. Before joining Amgen, from 2005 to 2006, Dr. Moore was a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs at Genentech, Inc. Prior to Genentech, she was a Postdoctoral Research Fellow at the Medical University of Lbeck, Germany since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 457 2700 |
| Web | https://www.allogene.com |
Alison Moore Latest Insider Activity
Tracking and analyzing the buying and selling activities of Alison Moore against Allogene Therapeutics stock is an integral part of due diligence when investing in Allogene Therapeutics. Alison Moore insider activity provides valuable insight into whether Allogene Therapeutics is net buyers or sellers over its current business cycle. Note, Allogene Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allogene Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Alison Moore over six months ago Acquisition by Alison Moore of 432738 shares of Allogene Therapeutics at 5.04 subject to Rule 16b-3 |
Allogene Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2582) % which means that it has lost $0.2582 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5415) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of December 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.57. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 22nd of December 2024, Non Current Assets Total is likely to grow to about 245.6 M, while Net Tangible Assets are likely to drop about 732.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yvonne Gehring | Arcus Biosciences | N/A | |
| Yuko JD | Sana Biotechnology | N/A | |
| Brian Austad | Karyopharm Therapeutics | N/A | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| Jim MBA | Fate Therapeutics | N/A | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Gary MD | Sana Biotechnology | N/A | |
| Amy CFA | Caribou Biosciences | N/A | |
| Barbara Hickingbottom | Fate Therapeutics | N/A | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| Sonja MD | Sana Biotechnology | 49 | |
| Roman Necina | Hookipa Pharma | 56 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Paul MD | Sana Biotechnology | N/A | |
| Lisa DiPaolo | Karyopharm Therapeutics | N/A | |
| Eric Hoefer | Arcus Biosciences | N/A | |
| William Grossman | Arcus Biosciences | 50 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Pia Eaves | Arcus Biosciences | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 |
Allogene Therapeutics Leadership Team
Elected by the shareholders, the Allogene Therapeutics' board of directors comprises two types of representatives: Allogene Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allogene. The board's role is to monitor Allogene Therapeutics' management team and ensure that shareholders' interests are well served. Allogene Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allogene Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Moore, Executive Officer | ||
| Rafael MD, Ex RD | ||
| Joshua Kazam, Co-Founder, Director | ||
| Geoffrey Parker, Executive CFO | ||
| FACS FACS, CoFounder Chairman | ||
| Susan Lundeen, Chief Officer | ||
| Veer Bhavnagri, G Officer | ||
| Earl Esq, General Officer | ||
| Christine Cassiano, Chief Officer | ||
| Annie Yoshiyama, Corporate VP | ||
| Yinlin Chen, Senior Finance | ||
| MD FACS, CoFounder Chairman | ||
| Alison Moore, Chief Technical Officer | ||
| David JD, Secretary | ||
| Eric Schmidt, Chief Officer | ||
| Stephen Cheng, Chief Officer | ||
| Barbra Sasu, Chief Scientific Officer |
Allogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allogene Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 185.66 M | ||||
| Shares Outstanding | 209.67 M | ||||
| Shares Owned By Insiders | 17.42 % | ||||
| Shares Owned By Institutions | 80.00 % | ||||
| Number Of Shares Shorted | 31.17 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 9,118 X |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.69 | DRTS | Alpha Tau Medical | PairCorr |
| 0.64 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.61 | VCYT | Veracyte | PairCorr |
| 0.6 | VCEL | Vericel Corp Ord | PairCorr |
| 0.58 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.